DE69423139T2 - Amid-Derivate mit anti-hypercholesterolemischer Wirkung, deren Herstellung und deren Verwendungen als Heilmittel - Google Patents

Amid-Derivate mit anti-hypercholesterolemischer Wirkung, deren Herstellung und deren Verwendungen als Heilmittel

Info

Publication number
DE69423139T2
DE69423139T2 DE69423139T DE69423139T DE69423139T2 DE 69423139 T2 DE69423139 T2 DE 69423139T2 DE 69423139 T DE69423139 T DE 69423139T DE 69423139 T DE69423139 T DE 69423139T DE 69423139 T2 DE69423139 T2 DE 69423139T2
Authority
DE
Germany
Prior art keywords
butyl
phenyl
reaction
xanthen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69423139T
Other languages
German (de)
English (en)
Other versions
DE69423139D1 (de
Inventor
Ichiro Hayakawa
Sadao Ishihara
Takashi Kasai
Eiichi Kitazawa
Teiichiro Koga
Hiroshi Kogen
Hiroyuki Koike
Kozo Oda
Fujio Saito
Akira Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of DE69423139D1 publication Critical patent/DE69423139D1/de
Application granted granted Critical
Publication of DE69423139T2 publication Critical patent/DE69423139T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/26—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/48—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C07D311/90—Xanthenes with hydrocarbon radicals, substituted by amino radicals, directly attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/12—[b,e]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DE69423139T 1993-06-30 1994-06-30 Amid-Derivate mit anti-hypercholesterolemischer Wirkung, deren Herstellung und deren Verwendungen als Heilmittel Expired - Fee Related DE69423139T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP16257293 1993-06-30

Publications (2)

Publication Number Publication Date
DE69423139D1 DE69423139D1 (de) 2000-04-06
DE69423139T2 true DE69423139T2 (de) 2000-11-16

Family

ID=15757145

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69423139T Expired - Fee Related DE69423139T2 (de) 1993-06-30 1994-06-30 Amid-Derivate mit anti-hypercholesterolemischer Wirkung, deren Herstellung und deren Verwendungen als Heilmittel

Country Status (22)

Country Link
US (2) US5534529A (enExample)
EP (1) EP0632036B1 (enExample)
JP (1) JPH0770021A (enExample)
KR (1) KR950000659A (enExample)
CN (1) CN1105984A (enExample)
AT (1) ATE190057T1 (enExample)
AU (1) AU672699B2 (enExample)
CA (1) CA2126994A1 (enExample)
CZ (1) CZ159394A3 (enExample)
DE (1) DE69423139T2 (enExample)
DK (1) DK0632036T3 (enExample)
ES (1) ES2143526T3 (enExample)
FI (1) FI943142A7 (enExample)
GR (1) GR3033020T3 (enExample)
HU (1) HUT67091A (enExample)
IL (1) IL110151A (enExample)
NO (1) NO942452L (enExample)
NZ (1) NZ260894A (enExample)
PT (1) PT632036E (enExample)
RU (1) RU2106340C1 (enExample)
TW (1) TW290546B (enExample)
ZA (1) ZA944739B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU699336B2 (en) 1995-05-16 1998-12-03 Toray Industries, Inc. A material for elimination or detoxification of super antigens
CZ272296A3 (en) * 1995-09-18 1997-04-16 Sankyo Co Novel derivatives of urea exhibiting acat inhibition activity, their preparation and therapeutic and prophylactic application
AU3172397A (en) * 1996-06-05 1998-01-05 Novartis Ag Anti-neurodegeneratively effective xanthene derivatives
DE69734773T2 (de) 1996-08-22 2006-07-20 Warner-Lambert Company Llc Nicht-peptidische Bombesin-Rezeptor-Antagonisten
WO1998021185A1 (en) * 1996-11-08 1998-05-22 Sankyo Company, Limited Arylureas or arylmethylcarbamoyl derivatives
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
RU2263109C2 (ru) * 1999-05-07 2005-10-27 Тексэс Байотекнолоджи Копэрейшн ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СЕЛЕКТИВНОГО ИНГИБИРОВАНИЯ СВЯЗЫВАНИЯ α4β1 ИНТЕГРИНА У МЛЕКОПИТАЮЩЕГО
WO2001017953A1 (en) * 1999-09-08 2001-03-15 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
MXPA03006666A (es) 2001-01-25 2004-05-31 Guilford Pharm Inc Compuestos de union de ciclofilina carbociclicos trisubstituidos y su uso.
KR20080008440A (ko) * 2003-03-17 2008-01-23 니뽄 다바코 산교 가부시키가이샤 Ｃｅｔｐ 억제제의 약제학적 조성물
BRPI0408442A (pt) * 2003-03-17 2006-04-04 Japan Tobacco Inc método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
PL2797416T3 (pl) 2011-12-28 2017-12-29 Global Blood Therapeutics, Inc. Podstawione związki benzaldehydowe i sposoby ich zastosowania do zwiększania natlenienia tkanek
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
BR112015021982B1 (pt) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos e seus usos para a modulação de hemoglobina
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP2968299B1 (en) 2013-03-15 2021-01-20 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
JP6426694B2 (ja) 2013-03-15 2018-11-21 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンの修飾のための化合物及びその使用
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
AP2016009261A0 (en) 2014-02-07 2016-06-30 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
PL3383392T3 (pl) 2015-12-04 2025-11-17 Global Blood Therapeutics, Inc. Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
CN109321940A (zh) * 2018-11-30 2019-02-12 西南大学 一种酰胺的电化学氧化合成方法及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4623662A (en) * 1985-05-23 1986-11-18 American Cyanamid Company Antiatherosclerotic ureas and thioureas
US4716175A (en) * 1987-02-24 1987-12-29 Warner-Lambert Company Saturated fatty acid amides as inhibitors of acyl-CoA:cholesterol acyltransferase
US5015644A (en) * 1987-06-02 1991-05-14 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds
IE61716B1 (en) * 1987-06-02 1994-11-30 Warner Lambert Co Antihyperlipidemic and antiatherosclerotic urea compounds
US4868210A (en) * 1988-03-30 1989-09-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
PT93158A (pt) * 1989-02-17 1990-08-31 Warner Lambert Co Processo para a preparacao de compostos de ureia trissubstituidos e de composicoes farmaceuticas que os contem
GB8921792D0 (en) * 1989-09-27 1989-11-08 May & Baker Ltd New compositions of matter
JPH05310678A (ja) * 1990-01-22 1993-11-22 Mitsubishi Kasei Corp １−フェニルアルキル−３−フェニル尿素誘導体
US5258405A (en) * 1990-03-12 1993-11-02 Yamanouchi Pharmaceutical Co., Ltd. Urea derivatives and salts thereof in method for inhibiting the ACAT enzyme
GB9017892D0 (en) * 1990-08-15 1990-09-26 May & Baker Ltd New compositions of matter
US5668136A (en) * 1990-09-25 1997-09-16 Eisai Co., Ltd. Trisubstituted benzene derivatives, composition and methods of treatment
JPH0694464B2 (ja) * 1991-01-23 1994-11-24 協和醗酵工業株式会社 三環式化合物およびその中間体
US5563169A (en) * 1991-09-13 1996-10-08 Sankyo Company, Limited Tricyclic heterocyclic compound

Also Published As

Publication number Publication date
ZA944739B (en) 1995-10-10
RU2106340C1 (ru) 1998-03-10
DE69423139D1 (de) 2000-04-06
PT632036E (pt) 2000-07-31
ES2143526T3 (es) 2000-05-16
AU6601294A (en) 1995-01-12
JPH0770021A (ja) 1995-03-14
HK1011967A1 (en) 1999-07-09
CA2126994A1 (en) 1994-12-31
FI943142A7 (fi) 1994-12-31
KR950000659A (ko) 1995-01-03
EP0632036B1 (en) 2000-03-01
IL110151A (en) 1998-10-30
FI943142A0 (fi) 1994-06-30
IL110151A0 (en) 1994-10-07
ATE190057T1 (de) 2000-03-15
CZ159394A3 (en) 1995-04-12
HUT67091A (en) 1995-01-30
HU9401943D0 (en) 1994-09-28
US5534529A (en) 1996-07-09
RU94022743A (ru) 1996-10-10
EP0632036A3 (en) 1995-01-18
AU672699B2 (en) 1996-10-10
EP0632036A2 (en) 1995-01-04
NO942452D0 (no) 1994-06-29
NO942452L (no) 1995-01-02
NZ260894A (en) 1995-05-26
US5614550A (en) 1997-03-25
GR3033020T3 (en) 2000-08-31
CN1105984A (zh) 1995-08-02
DK0632036T3 (da) 2000-06-05
TW290546B (enExample) 1996-11-11

Similar Documents

Publication Publication Date Title
EP0632036B1 (en) Amide derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
DE68927904T2 (de) Fumagillol-Derivate
DE68915900T2 (de) Angiogenese hemmendes Mittel.
DE69418704T2 (de) Anthranilsäure derivate
DE60036726T2 (de) Harnstoff derivate als entzündungshemmende mittel
DE69815008T2 (de) Alfa-substituierte Phenylpropionsäurederivate und diese enthaltende Arzneimittel
DE60127595T2 (de) Inhibitoren der TNF-Alpha Bildung zur Behandlung von Autoimmunerkrankungen
EP0726899B1 (de) Neue pyrazincarboxamidderivate, ihre herstellung und ihre verwendung in arzneimitteln
EP0004920A1 (de) Carbazolyl-(4)-oxy-propanolamin-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
SK281857B6 (sk) Dihydrobenzofurány, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
EP0000928A1 (de) Neue Nitroimidazole und diese enthaltende pharmazeutische Präparate sowie deren Herstellung
US6890932B2 (en) Anthranilic acid derivative
JPS61155358A (ja) ジアリール酪酸誘導体
EP0485984B1 (en) Diarylmethoxypiperidine derivatives
EP0599203A1 (de) N,n,-Disubstituierte Arylcycloalkylamine, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu iher Herstellung
US4457931A (en) Piperazine derivatives with anticholinergic and/or antihistaminic activity
DE3305569A1 (de) Biscarboxamide zur bekaempfung von erkrankungen sowie verfahren zu ihrer herstellung
DE69004598T2 (de) 6-Amino-6-desoxyfumagillole, ihre Herstellung und ihre Verwendung.
US4405642A (en) Method for treatment or prophylaxis of cardiac disorders
DE69014798T2 (de) Thionaphthalen-derivate, verfahren zur herstellung und antiallergisches mittel daraus.
US4294972A (en) 1,2-Disubstituted oxo triazolidine
DE69714040T2 (de) Taxane derivate, ihre herstellung und zusammensetzungen die sie enthalten
DE69405815T2 (de) Acylharnstoffe
GB2238542A (en) 4-Phenoxyphenyl esters of substituted carbamic acids
DE69620175T2 (de) Hydroxylamin-derivate mit anti-ischämischer wirkung und pharmazeutische zusammensetzungen diese enthaltend

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee